We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Harrow Inc (HROW) USD0.001

Sell:$50.50 Buy:$52.00 Change: $0.62 (1.25%)
Market closed |  Prices as at close on 4 October 2024 | Switch to live prices |
Sell:$50.50
Buy:$52.00
Change: $0.62 (1.25%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 4 October 2024 | Switch to live prices |
Sell:$50.50
Buy:$52.00
Change: $0.62 (1.25%)
Market closed |  Prices as at close on 4 October 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Contact details

Address:
102 WOODMONT BLVD, SUITE 610
NASHVILLE
37215
United States
Telephone:
+1 (615) 7334731
Website:
https://www.harrow.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
HROW
ISIN:
US4158581094
Market cap:
$1.63 billion
Shares in issue:
35.48 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Mark Baum
    Chairman of the Board, Chief Executive Officer
  • Andrew Boll
    Chief Financial Officer, Corporate Secretary
  • John Saharek
    President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.